07:00 Mon 01 Mar 2021
e-Therapeutics plc - Change of Adviser
e-therapeutics plc
("e-therapeutics" or the "Company")
Change of Adviser
Director Disclosure
The Company also announces the following additional information in accordance with paragraph (g) of Schedule Two to the AIM Rules for Companies in respect of
Enquiries:
e-therapeutics plc |
|
|
Tel: +44 (0)1993 883 125 |
|
|
|
|
SP Angel Corporate Finance LLP |
Tel: +44(0)20 3470 0470 |
Nominated Adviser and Broker |
|
|
|
|
|
|
|
About e-therapeutics plc
e-therapeutics plc is an
e-therapeutics has developed an in silico laboratory that enables the rapid screening of millions of compounds and the identification of small sub-sets that are enriched for highly active hits. Its proprietary platform also has novel applications in functional genomics, being able to analyse complex genetic datasets, provide a deep understanding of pathological mechanisms and distil actionable insights for the discovery of novel drugs, biomarkers and diagnostics.
e-therapeutics has deployed and validated its disease-agnostic drug discovery platform both in house and with partners, including Novo Nordisk, Galapagos NV and a US-based, top 5 pharmaceutical company.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of...
FOR OUR FULL DISCLAIMER CLICK HERE